Company Overview

Actuate Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing targeted therapies for cancers and other difficult-to-treat diseases. The company’s core scientific platform centers on glycogen synthase kinase-3 (GSK-3) inhibition, with its lead product candidate, elraglusib (formerly known as 9-ING-41), being evaluated across multiple oncology indications. Actuate operates within the biotechnology and oncology drug development industries, with an emphasis on combination therapies designed to enhance the effectiveness of existing cancer treatments.

The company’s primary revenue and enterprise value drivers are tied to the clinical advancement, licensing potential, and commercialization prospects of its drug candidates, particularly elraglusib. Actuate has focused on cancers with high unmet medical need, including pancreatic cancer, glioblastoma, and other advanced solid tumors. The company was founded in 2015 and evolved from an early-stage oncology research organization into a publicly traded clinical-stage biotechnology company following its Nasdaq listing under the ticker ACTU. Its strategic positioning is based on differentiated GSK-3 inhibition technology and the potential applicability of its platform across multiple tumor types and therapeutic combinations.

Business Operations

Actuate Therapeutics primarily operates through its oncology drug development programs, with research and clinical operations centered around elraglusib. The company generates no significant commercial product revenue as of publicly available filings and instead relies on financing activities, public market capital raises, and strategic collaborations to fund operations. Its business model is typical of development-stage biotechnology companies, emphasizing clinical trials, regulatory advancement, intellectual property development, and potential future licensing arrangements.

The company’s operations include conducting multicenter clinical trials in the United States and internationally through partnerships with clinical research organizations, academic cancer centers, and healthcare institutions. Actuate maintains intellectual property related to GSK-3 inhibition and associated therapeutic applications. Public disclosures identify collaborations involving combination studies with established chemotherapy agents and immuno-oncology approaches. Data regarding material joint ventures or large-scale commercial subsidiaries remains limited based on available public sources.

Strategic Position & Investments

Actuate Therapeutics’ strategic direction is focused on advancing elraglusib through later-stage clinical development and expanding its use in combination treatment regimens. A significant area of emphasis has been metastatic pancreatic ductal adenocarcinoma and other aggressive cancers where current treatment outcomes remain poor. The company has pursued clinical development strategies involving combination therapy with standard-of-care chemotherapies and checkpoint inhibitors in an effort to improve efficacy outcomes.

The company’s investments are concentrated in clinical trial expansion, regulatory engagement, intellectual property protection, and biomarker-driven oncology research. Public filings and investor materials indicate ongoing evaluation of additional indications where GSK-3 inhibition may have therapeutic relevance. Actuate has also emphasized the potential broader role of GSK-3 modulation in cancer biology and treatment resistance mechanisms. No major acquisition activity or extensive portfolio company structure has been publicly disclosed in verified filings.

Geographic Footprint

Actuate Therapeutics is headquartered in Fort Worth, Texas, and primarily operates within the United States biotechnology and clinical research ecosystem. Its clinical activities involve collaboration with cancer treatment centers and research institutions across multiple U.S. regions. The company’s Nasdaq listing has also expanded its visibility within international capital markets.

Internationally, Actuate participates in global clinical development through trial sites and research collaborations outside the United States, although its operational footprint remains relatively concentrated compared with larger multinational pharmaceutical companies. Publicly available information indicates exposure to clinical and regulatory activities in North America and selective international markets tied to oncology trial enrollment and research partnerships.

Leadership & Governance

Actuate Therapeutics was co-founded by oncology-focused executives and scientists seeking to commercialize GSK-3 inhibition therapies. The company’s leadership has emphasized disciplined clinical execution, targeted oncology development, and the pursuit of differentiated therapies for cancers with significant unmet medical need. Governance and operational strategy are guided through executive leadership, scientific advisory participation, and oversight from the company’s board of directors.

Key executives identified in public filings and corporate disclosures include:

• Daniel Schmitt – Chief Executive Officer
• Mark B. Logan, M.D. – Chief Medical Officer
• Andrew J. Hull, Ph.D. – Chief Scientific Officer
• Michael N. Mainolfi – Chief Business Officer

The leadership team’s strategic vision has focused on advancing precision oncology therapies through evidence-driven clinical development, strategic capital formation, and partnership-oriented research initiatives. Public disclosures emphasize a science-led operating philosophy centered on translational medicine and combination-based oncology treatment approaches.